Headquarters

5959 Horton St, Floor 7
Emeryville, California 94608

© 2026 Metagenomi

Novel Proprietary Systems

Enabling precise and durable genetic correction to transform outcomes for people with genetic diseases

Matching the right tool for each therapeutic target

Genet­ic muta­tions are seen in a vari­ety of forms, includ­ing dele­tions, inser­tions, sin­gle base pair changes and sequence repeats across a vari­ety of dif­fer­ent cell types, tis­sues, and organ sys­tems. Addi­tion­al­ly, many dis­eases lack a genet­ic ori­gin but have the poten­tial to be effec­tive­ly and per­ma­nent­ly addressed through genome editing.

At Metageno­mi, we are har­ness­ing the pow­er of metage­nomics to dis­cov­er and devel­op a suite of nov­el edit­ing tools capa­ble of cor­rect­ing any type of genet­ic muta­tion found any­where in the genome. Our com­pre­hen­sive genome edit­ing capa­bil­i­ties include pro­gram­ma­ble nucle­as­es, base edi­tors, as well as RNA and DNA-medi­at­ed inte­gra­tion sys­tems (includ­ing prime edit­ing sys­tems and CASTs). Giv­en the tar­get­ing den­si­ty of our nucle­ase library, we believe that essen­tial­ly any codon in the human genome could be addressed with our gene edit­ing systems.

Programmable Nucleases

Multiple nucleases to edit any target in the human genome

Our capa­bil­i­ties con­tain thou­sands of CRISPR nucle­as­es allow­ing us to select the ide­al sys­tem for tar­get­ing any giv­en gene in a site-spe­cif­ic man­ner, poten­tial­ly over­com­ing a major lim­i­ta­tion of first-gen­er­a­tion CRISPR sys­tems. In order to mod­i­fy the genome, nucle­as­es are used to cre­ate tar­get­ed genom­ic breaks, trig­ger­ing DNA repair path­ways. This allows us to inte­grate a gene at a tar­get site (knock-in), or deac­ti­vate a gene (knock-down). 

Ultra-Small Systems

Ultra-small nucleases to expand in vivo delivery options

Our ultra-small nucle­as­es are high­ly effi­cient genome edit­ing sys­tems that have the poten­tial for exten­sive ther­a­peu­tic appli­ca­tions. We have pri­or­i­tized find­ing sys­tems to over­come the size con­straints of first gen­er­a­tion nucle­as­es. Our sys­tems are a frac­tion of the size and pack­age eas­i­ly into a sin­gle AAV for tar­get­ing organs beyond what is pos­si­ble with lipid nanopar­ti­cle delivery.

Base Editors

Single nucleotide changes

We lever­age our capa­bil­i­ties of pro­gram­ma­ble nucle­as­es to devel­op a high­ly tar­getable base edit­ing plat­form com­pat­i­ble with a vari­ety of deliv­ery tech­nolo­gies. We have dis­cov­ered and engi­neered what we believe to be the small­est CRISPR base edi­tors known. These ultra-small base edi­tors, when deliv­ered in an AAV, could allow us to address neu­ro­mus­cu­lar dis­or­ders in the CNS.

RNA Mediated Integration Systems (RIGS)

Genomic replacements and insertions

Metageno­mi’s RIGS make pro­gram­ma­ble genom­ic mod­i­fi­ca­tions that are encod­ed in RNA tem­plates. Using RIGS we can achieve small edits (prime edit­ing), as well as large edits. Our RIGS plat­form allows us to address more com­plex gene edits such as inser­tions, dele­tions, and all types of point mutations. 

CRISPR Associated Transposases (CASTs)

Large gene integrations

Direct­ed DNA inte­gra­tion has large­ly been con­sid­ered the ulti­mate goal of cor­rec­tive genome edit­ing. This tech­nol­o­gy has the poten­tial to address a large col­lec­tion of com­plex genet­ic dis­eases caused by any loss of func­tion muta­tions, such as cys­tic fibro­sis, where inser­tions of greater than 10,000 bp would be required to address all muta­tions. Our CASTs are being devel­oped to per­form these com­plex gene integrations.

Diverse toolbox

Diverse Capabilities

Our expansive genome editing capabilities enable broad therapeutic applications

Precision

Pre­ci­sion & Efficiency

Our capabilities have the potential to target any codon in the human genome with high precision and efficiency

Ultra small

Ultra-Small Systems

Our compact systems offer advantages for viral and non-viral in vivo delivery

Rapid development

Rapid Development

Our highly active natural nucleases and effectors shorten optimization period

Modularity

Modular Engineering

Chimeras enable access to untargetable sites for precision edits and repairs

Owned ip

Wholly-Owned IP

Diverse enzymes with novel IP and unique characteristics derived from proprietary library

Delivery

Our genome editing capabilities were designed to have broad com­pat­i­bil­i­ty with viral and non­vi­ral deliv­ery technologies

Non viral

Non-Viral

We deploy LNP technology for efficient delivery of our gene editing systems to target organs such as the liver in order to address hemophilia, and other metabolic and cardiovascular diseases.

Viral

Viral

The ability to package our systems into a single AAV enables us to unlock extrahepatic targets, including those in the CNS and in muscle.

Disease Focus Areas

Strategically advancing genetic medicines

Ther­a­peu­tic Approach
Liver cardiovascular

Liver and Cardiovascular

Our initial therapeutic programs targeting the liver aim to treat diseases that have well-defined biology, readily available translational biomarkers for early proof-of-concept, established development pathways based on prior drug approvals, and important unmet medical needs. Additionally, we are utilizing in vivo editing approaches to target key genes associated with major cardiovascular causes of morbidity and mortality.

Cns muscle

CNS and Muscle

These diseases are caused by diverse mutations that require precision deletions and corrections to address the underlying cause. By optimizing a suite of small, next generation systems we are systematically deploying our capabilities to develop potentially curative therapies for patients with neurodegenerative and neuromuscular diseases.

Posters & Publications

View more